The stock is trading at $1.04 barely below the 50 day moving average which is $1.13 and barely above the 200 day moving average of $0.98. The 50 day moving average went down by -8.28% and the 200 day average moved up $0.06. Trading was light with 332K shares changing hands on Tuesday. Overall, volume was down 14.99% under the stocks normal daily volume.
Investors are a little more bullish on shares of the company looking at the motion in short interest. The stock realized a fall in short interest of -9.67% as of the latest report on October 13, 2017. Short shares fell 41,692 over that period. Days to cover decreased 0.0 to 1.0 and the percentage of shorted shares was 0.00% on October 13.
The following firms have recently changed their position in BLRX. Dafna Capital Management LLC reduced its position by selling 19,648 shares a decrease of 2.0% in the quarter. Dafna Capital Management LLC currently owns 980,352 shares with a value of $828,000. The total value of its holdings decreased 13.8%. Alyeska Investment Group, L.p. trimmed its investment by shedding 1,370,424 shares a decrease of 60.9%. Alyeska Investment Group, L.p. now controls 879,576 shares valued at $743,000. The value of the position overall is down by 65.6%.
As of quarter end Sabby Management, LLC had disposed of 192,705 shares trimming its position 6.1%. The value of the investment in (BLRX) went from $3,018,000 to $2,507,000 a change of 16.9% since the last quarter. Benchmark Capital Advisors expanded its ownership by buying 2,000 shares an increase of 1.4% as of 09/30/2017. Benchmark Capital Advisors controls 146,000 shares worth $164,000. The value of the position overall is up by 34.4%.
On August 4 analysts at Oppenheimer starting coverage on BLRX setting a rating of “Outperform”.
In the latest earnings report the EPS was $-0.28 and is projected to be $-0.24 for the current year with 95,617,000 shares outstanding. Analysts expect next quarter’s EPS to be $-0.06 and the next full year EPS is anticipated to be $-0.02.
BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. Its development pipeline consists of three primary clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; BL-7010, a novel co-polymer for the treatment of celiac disease and gluten sensitivity; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. The company’s other therapeutic candidates comprise BL-8020, an orally available treatment for the hepatitis C virus, and other viral indications; and BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction. It also has a preclinical stage therapeutic candidate, BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas. The company has strategic collaboration with Novartis Pharma AG; and a collaboration with Merck. BioLineRx Ltd. was founded in 2003 and is headquartered in Modi’in, Israel..